编者按 - BASIL试验中初次旁路与球囊扩张失败后二次旁路的临床结局比较
BASIL试验比较初次旁路(PB)与初次球囊扩张(PBA)失败后二次旁路(SB)的临床结局。190例PB与49例SB患者中位随访7年,PB的无截肢生存(60% vs 40%,HR 1.58,p=.04)更优,保肢与总生存无显著差异,免于再血管化两组相当。
要点
- PB组无截肢生存显著优于SB组(60% vs 40%,HR 1.58,p=.04)。
- 保肢(85% vs 73%,p=.06)与总生存(68% vs 51%,p=.06)无显著差异。
- 免于再血管化两组相当(53% vs 53%,p=.3)。
核心结论
- BASIL试验中,初次旁路的临床结局显著优于球囊扩张失败后的二次旁路。
- 作者认为,对慢性肢体威胁性缺血患者行初次球囊扩张前,临床医生应考虑一旦失败,后续旁路结局可能显著差于初次旁路。
研究设计与样本
- BASIL试验数据的事后比较分析,PB组190例,SB组49例。
主要发现
- 中位随访7年,PB组无截肢生存60% vs SB组40%(HR 1.58,p=.04)。
- PB组保肢85% vs SB组73%(p=.06)。
- PB组总生存68% vs SB组51%(p=.06)。
- 免于再血管化PB组53% vs SB组53%(p=.3)。
- SB组当前吸烟者更多,其余基线匹配良好。
临床怎么用
- 作者认为,对慢性肢体威胁性缺血患者行初次球囊扩张前,临床医生应考虑一旦失败,后续旁路结局可能显著差于初次旁路。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chronic limb threatening ischaemia (CLTI) is a growing global health problem. The UK NIHR HTA funded BASIL trial is still the only randomised controlled trial to have compared a "bypass surgery first" with a "plain balloon angioplasty (PBA) first" strategy for the management of CLTI. In patients who were likely to survive for 2 years and had a suitable vein, primary bypass (PB) was associated with better clinical outcomes. Furthermore, PBA was associated with a high technical and clinical failure rate and many went on to have secondary bypass (SB). This study aimed at comparing clinical outcomes following PB and SB in the BASIL trial. METHODS: Demographic, procedural, and outcome data were obtained from the BASIL case report forms. Outcomes were amputation free survival (AFS), limb salvage (LS), overall survival (OS), and freedom from revascularisation (FFR). The SB cohort comprises patients whose first trial intervention was PBA and who subsequently underwent bypass during follow up. The PB cohort comprises those patients whose first trial intervention was bypass. RESULTS: The 190 PB and 49 SB patients were well matched except that the SB patients were more likely to be current smokers. At a median of 7 years, PB was associated with better AFS (PB 60% vs. SB 40%; HR 1.58, p = .04), LS (PB 85% vs. SB 73%, p = .06), and OS (PB 68% vs. 51%, p = .06). FFR was equivalent (PB 53% vs. 53%, p = .3). CONCLUSION: In the BASIL trial, clinical outcomes following PB were significantly better than in patients undergoing SB after failed PBA. Prior to treating patients with CLTI with primary PBA, clinicians should consider that if this should fail, the outcome of attempted subsequent bypass is likely to be significantly worse than if PB were attempted.
引用
- Meecham L, Patel S, Bate GR, et al. Editor's Choice - A Comparison of Clinical Outcomes Between Primary Bypass and Secondary Bypass After Failed Plain Balloon Angioplasty in the Bypass versus Angioplasty for Severe Ischaemia of the Limb (BASIL) Trial. Eur J Vasc Endovasc Surg. 2018. PMID: 29599067. doi:10.1016/j.ejvs.2018.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。